31 results
8-K
EX-99.3
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
, and the managing partner and CEO of Avista Capital Partners. Avista has a successful track record of building sustainable growth health care companies for over … approvals – positions OmniAb well for continued sustainable growth.
We believe that Avista’s experience, combined with the equity investment
425
EX-99.3
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
23 Mar 22
Business combination disclosure
5:29pm
, and the managing partner and CEO of Avista Capital Partners. Avista has a successful track record of building sustainable growth health care companies for over … approvals – positions OmniAb well for continued sustainable growth.
We believe that Avista’s experience, combined with the equity investment
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
8 May 13
Ligand Reports First Quarter Financial Results
12:00am
sustainable cash flow, which has allowed us to pay down debt earlier than planned and to announce a share repurchase program today. These initiatives speak … and, under its lean corporate cost structure, produce sustainable profitability. Ligand has a diverse asset portfolio addressing the unmet medical
425
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
31 Aug 09
Business combination disclosure
12:00am
and diversity of its partnered pipeline make it a sustainable, revenue generating business over the long haul.
“There are peer companies that have created … sustainable because cash flows go away,” he said.
In contrast, Higgins said, “we have a long list of partners across a whole range of therapeutic areas
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
4 Dec 13
Ligand Raises Fourth Quarter and Full Year 2013 Financial Forecast
12:00am
assets through licensing and acquisition with the goal to generate sustainable cash flow and profitability. Ligand has a diverse asset portfolio
8-K
EX-99.1
z1l412g
20 Jun 13
Ligand Raises Ownership Limit for BVF Partners to 25% of Shares Outstanding
12:00am
8-K
EX-99.1
mk9ujsae 1v
24 Jul 13
Ligand Signs License Agreement with Ethicor for Oral Lasofoxifene
12:00am
8-K
EX-99.1
95lspa1 lunxg
22 Jul 13
Ligand Signs Global License Agreement with Azure for Lasofoxifene
12:00am
8-K
EX-99.1
wt59lr7c5i5vpr8av
22 Oct 12
Ligand to Receive $2 Million Milestone Payment from Merck Triggered by Initiation of Phase 2b/3 Trial of Dinaciclib
12:00am
8-K
EX-99.1
wrv3t1
14 Mar 13
Ligand Signs Global License Agreement with Spectrum Pharmaceuticals for Captisol-Enabled® Melphalan
12:00am
8-K
EX-99.1
um7j5qomz1p5fr34j tn
11 Aug 14
Ligand Announces Proposed Offering of $225 Million of Convertible Senior Notes
12:00am
8-K
EX-99.1
k8sreb47i7
5 Nov 12
Ligand Pharmaceuticals to Restate Previous Financial Statements
12:00am
8-K
EX-99.2
7h27bho0pcindqk
4 Dec 12
Regulation FD Disclosure
12:00am
8-K
EX-99.1
jxexbpg3s8ktu hqjl
14 Dec 12
Other Events
12:00am
8-K
EX-99.1
36lxpexvpa
13 Aug 14
Ligand Prices Offering of $225 Million of Convertible Senior Notes
12:00am
8-K
EX-99.1
0jgiygtfh 1895asg
19 Nov 12
Other Events
12:00am
8-K
EX-99.1
6oy2vosham zj
5 Nov 12
Ligand Pharmaceuticals Reports Preliminary Third Quarter 2012 Results
12:00am
8-K
EX-99.1
411fcwff52 su
4 Dec 12
Regulation FD Disclosure
12:00am
8-K
EX-99.1
ik6fmb303mr
30 Oct 13
Ligand Reports Third Quarter Financial Results
12:00am
8-K
EX-99.1
gb5f93d7n9 f4j9
13 Feb 13
Ligand Reports Fourth Quarter and Full Year 2012 Financial Results
12:00am